Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 8/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL6557342 | 0.90 | PIK3CG (0.36) | PIK3CG | |
| SCHEMBL21657798 | 0.87 | PIK3CG (0.36) | PIK3CGEGFRCYP11B1CYP11B2 | |
| SCHEMBL21657921 | 0.87 | PIK3CG (0.36) | PIK3CGCYP11B1CYP11B2 | |
| SCHEMBL22792590 | 0.83 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL3292267 | 0.78 | PIK3CG (0.47) | PIK3CGEGFR | |
| SCHEMBL1378685 | 0.75 | PIK3CG (0.46) | PIK3CGEGFR | |
| SCHEMBL12338373 | 0.74 | PIK3CG (0.34) | PIK3CGEGFR | |
| SCHEMBL12120583 | 0.74 | PIK3CG (0.34) | PIK3CGEGFR | |
| SCHEMBL30792962 | 0.74 | PIK3CG (0.35) | PIK3CGEGFRCYP11B1CYP11B2 | |
| SCHEMBL30290978 | 0.72 | PIK3CG (0.41) | PIK3CGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| EP-0975791-A1 | MARINE BACTERIAL STRAIN OF THE GENUS VIBRIO, WATER-SOLUBLE POLYSACCHARIDES PRODUCED BY SAID STRAIN AND THEIR USES | IFREMER INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998038327-A1 | MARINE BACTERIAL STRAIN OF THE GENUS VIBRIO, WATER-SOLUBLE POLYSACCHARIDES PRODUCED BY SAID STRAIN AND THEIR USES | INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER) (FR) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | PIK3CG 2123/4885EGFR 3332/4885CYP11B1 176/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | PIK3CG 2285/4885EGFR 3146/4885CYP11B1 133/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | PIK3CG 1929/4885EGFR 1832/4885CYP11B1 189/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | PIK3CG 1929/4885EGFR 1832/4885CYP11B1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.